0
Boehringer Ingelheim’s market leading Animal Health medication Metacam® (active ingredient: Meloxicam) obtained EU wide marketing authorization as an oral suspension in a concentration of 15 mg/ml for use in pigs. Metacam® reduces symptoms of lameness and inflammation in animals suffering from non-infectious locomotor disorders and acts as adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (Mastitis-Metritits-Agalactia syndrome, MMA).Following the positive opinion of the CVMP, the European Medicines Agency’s (EMA) scientific committee, the EU commission today announced their decision to authorize this new formulation of Metacam® for pigs.
Metacam® 15 mg/ml is a further formulation of a successful concept of inflammation control that helps restore productivity and well being in pigs. It offers an additional option to vets and farmers that increases convenience and stress reduction:
“Metacam® 15 mg/ml oral suspension is all about choices which we try to offer to the swine producer enabling him to better adjust the administration of a needed treatment to specific conditions“, says Dr. Joachim Hasenmaier, Head of Corporate Animal Health at Boehringer Ingelheim.*
Individual preferences or specific managerial situations can make the oral application of Metacam® more convenient.
*
Situation specific welfare considerations such as in freshly farrowed sows which are particularly sensitive to stress can be another motivation to prefer the oral application over an injection.
Metacam® is a non-steroidal anti-inflammatory drug of the oxicam class. Metacam® was first launched for pigs in 2003, and is now licensed in over 40 countries around the world.
http://www.boehringer-ingelheim.com
